Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.: Influence Statistics

Expert Impact

Concepts for which they have has direct influence: Heart failure , Preserved ejection fraction , Patients hfpef , Ejection fraction , Preserved ejection , Failure preserved , Stroke volume .

Key People For Heart Failure

Top KOLs in the world
John J J V McMurray
heart failure myocardial infarction atrial fibrillation
John George Franklin Cleland
heart failure patients hf atrial fibrillation
Stephan D Anker
heart failure iron deficiency cardiac cachexia
Greegg C Fonarow
heart failure atrial fibrillation united states
Karl B Swedberg
heart failure reduced ejection fraction myocardial infarction
Piotr P Ponikowski
heart failure iron deficiency reduced ejection fraction

Global Differences in Heart Failure With Preserved Ejection Fraction: The PARAGON-HF Trial.


. BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) is a global public health problem with important regional differences. We investigated these differences in the PARAGON-HF trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin Receptor Blocker Global Outcomes in HFpEF), the largest and most inclusive global HFpEF trial. METHODS: We studied differences in clinical characteristics, outcomes, and treatment effects of sacubitril/valsartan in 4796 patients with HFpEF from the PARAGON-HF trial, grouped according to geographic region. RESULTS: Regional differences in patient characteristics and comorbidities were observed: patients from Western Europe were oldest (mean 75±7 years) with the highest prevalence of atrial fibrillation/flutter (36%); Central/Eastern European patients were youngest (mean 71±8 years) with the highest prevalence of coronary artery disease (50%); North American patients had the highest prevalence of obesity (65%) and diabetes (49%); Latin American patients were younger (73±9 years) and had a high prevalence of obesity (53%); and Asia-Pacific patients had a high prevalence of diabetes (44%), despite a low prevalence of obesity (26%). Rates of the primary composite end point of total hospitalizations for HF and death from cardiovascular causes were lower in patients from Central Europe (9 per 100 patient-years) and highest in patients from North America (28 per 100 patient-years), which was primarily driven by a greater number of total hospitalizations for HF. The effect of treatment with sacubitril-valsartan was not modified by region (interaction P>0.05). CONCLUSIONS: Among patients with HFpEF recruited worldwide in PARAGON-HF, there were important regional differences in clinical characteristics and outcomes, which may have implications for the design of future clinical trials. Registration: URL:; Unique identifier: NCT01920711.